What it is
Retatrutide is a synthetic peptide developed by Eli Lilly that acts as a single-molecule agonist at three distinct hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This triple receptor engagement is the key distinction from earlier obesity drugs. GLP-1 agonists like semaglutide activate one receptor; dual agonists like tirzepatide activate two (GIP and GLP-1). Retatrutide adds glucagon receptor agonism, which independently promotes energy expenditure and fatty acid oxidation in the liver. [3]
The compound is not FDA-approved and is not available through any approved pharmaceutical channel. As of 2026, it is in Phase 3 clinical trials for obesity and type 2 diabetes under Eli Lilly's development program. Research-grade retatrutide sold by peptide vendors is not equivalent to the pharmaceutical compound used in those trials.
What researchers study it for
- Obesity and body weight reduction The Phase 2 NEJM trial (Jastreboff et al., 2023) enrolled 338 adults with obesity and randomized them to retatrutide or placebo over 48 weeks. At the highest dose (12 mg weekly), the mean weight reduction was approximately 24.2%, compared to 2.1% with placebo. This represented the largest mean weight loss observed in a clinical trial for an anti-obesity medication at the time of publication. [1]
- Metabolic dysfunction-associated steatotic liver disease (MASLD) A parallel Phase 2 analysis published in Nature Medicine found that retatrutide treatment was associated with substantial reductions in liver fat content assessed by MRI, with a significant proportion of participants achieving resolution of steatosis at 48 weeks. The glucagon receptor component is thought to contribute through direct hepatic fatty acid oxidation effects. [2]
- Cardiometabolic risk factors Beyond weight reduction, the Phase 2 trial documented improvements in blood pressure, triglycerides, waist circumference, and glycemic markers. Researchers have noted that the glucagon agonism contributes energy expenditure effects that may help explain why retatrutide's weight reduction exceeds that of GLP-1 or dual GIP/GLP-1 agonists at similar tolerability profiles. [3]
- Obesity-associated cancer biology Preclinical work has examined whether retatrutide-associated weight loss modulates tumor biology in obesity-associated cancers. A 2025 study in NPJ Metabolic Health and Disease found that retatrutide treatment in preclinical models reduced obesity-driven tumor growth, suggesting potential research applications beyond metabolic endpoints. [4]
Research context
Retatrutide has the strongest Phase 2 weight loss data of any obesity compound yet published. The 24% mean weight reduction in the NEJM trial is clinically meaningful by any benchmark, and the MASLD findings add a hepatic dimension that positions the compound for a broad cardiometabolic indication. [1] [2] The addition of glucagon receptor agonism is both the compound's distinguishing feature and the element requiring the most careful safety monitoring: sustained glucagon activity can raise blood glucose and heart rate, and the long-term metabolic consequences of triple receptor co-stimulation in humans are still being characterized in the ongoing Phase 3 program.
The obesity drug landscape is moving rapidly. Tirzepatide (dual GIP/GLP-1) was approved in 2022 and 2023, and retatrutide may follow pending Phase 3 outcomes. Researchers following this compound should treat the Phase 2 findings as hypothesis-generating: the sample size, duration, and patient populations in those trials were not designed to detect cardiovascular outcomes, long-term weight maintenance, or safety signals requiring larger exposure. Phase 3 results will be the determining evidence. [3]
Typical research parameters
| Parameter | Detail |
|---|---|
| Common vial sizes | Varies by vendor; 5 mg and 10 mg most common for research supply |
| Supplied as | Lyophilized powder |
| Administration studied | Once-weekly subcutaneous injection in all published clinical trials [1] |
| Dose range (Phase 2) | 0.5 mg to 12 mg weekly; weight loss was dose-dependent up to 12 mg [1] |
| Half-life | Approximately 6 days in humans (supports once-weekly dosing) |
| Regulatory status | Not FDA-approved; Phase 3 trials ongoing as of 2026 |
References
- [1] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389. PubMed ↗
- [2] Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30. PubMed ↗
- [3] Tetelbaun L, Mullally JA, Frishman WH. The First Triple Agonist for Antiobesity: Retatrutide. Cardiology in Review. 2024. PubMed ↗
- [4] Marathe SJ, Grey EW, Bohm MS, et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. NPJ Metabolic Health and Disease. 2025. PubMed ↗